Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
20 Mar 2024
Financial Statement
GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at .
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonistGLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit .
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.